Strategies for management of patients with, or at risk for, medication-related osteonecrosis of
the jaws (MRONJ)–formerly referred to as bisphosphonate-related osteonecrosis of the jaws …

The goal of osteoporosis management is to prevent fractures. Several pharmacological
agents are available to lower fracture risk, either by reducing bone resorption or by …

Osteoporosis is the most common metabolic bone disease in the USA and the world. It is a
subclinical condition until complicated by fracture (s). These fractures place an enormous …

Abstract Summary The National Osteoporosis Guideline Group (NOGG) has revised the UK
guideline for the assessment and management of osteoporosis and the prevention of …

Objective The objective is to formulate clinical practice guidelines for the pharmacological
management of osteoporosis in postmenopausal women. Conclusions Evidence from …

Abstract Introduction In 2008, the UK National Osteoporosis Guideline Group (NOGG)
produced a guideline on the prevention and treatment of osteoporosis, with an update in …

PURPOSE To provide guidance regarding best practices in the prevention and
management of medication-related osteonecrosis of the jaw (MRONJ) in patients with …

Key Clinical Points Postmenopausal Osteoporosis Fractures and osteoporosis are common,
particularly among older women, and hip fractures can be devastating. Treatment is …

Skeletal complications caused by osteoporosis or bone metastases are associated with
considerable pain, increased mortality, and reduced quality of life. Furthermore, such events …

Glucocorticoid-induced osteoporosis is the most common secondary cause of osteoporosis
and the resulting fractures cause significant morbidity. Following initiation of oral …